In 2025, Emison ACHieved revenue of RMB 15.419 million, up 113% YoY, with gross margin surging from 56.9% to 78.1%. The company holds 5 NMPA Class III medical device registrations, ranking first among methylation technology companies in China. Core product AiGuangLe (艾光乐) for urothelial carcinoma received NMPA approval in October 2025, becoming the company's 5th Class III certificate. On April 7, 2026, Emison filed its second IPO application with the Hong Kong Stock Exchange (initial filing: September 28, 2025), jointly sponsored by CCB International and BOCOM International.
Company Profile (Updated April 2026)
Emison Life Science Technology Co., Ltd. (武汉艾米森生命科技股份有限公司) is a pioneering Chinese early cancer detection company specializing in methylation-based molecular diagnostics. Founded in January 2015 in Wuhan Optics Valley, Hubei Province, china by Dr. Zhang Lianglu (张良禄), a former pathologist who left clinical practice at age 27 to pursue entrepreneurship, the company has developed a proprietary AI + methylation detection technology platform strategically focused on high-incidence, high-mortality cancers.
Development History:
- 2015: Established in Wuhan, China, focusing on methylation-based cancer early detection technology
- 2016: Dr. Zhang Lianglu selected as a ＂3551 Optics Valley Talent Plan＂ entrepreneurial talent; co-founder Dong Lanlan joined as R&D President
- 2022: After 7 years of R&D, flagship product AiChangKang (艾长康), the world's first dual-target fecal DNA methylation colorectal cancer detection kit, received NMPA Class III registration
- 2023: AiChangKang and AiChangJian (艾长健) obtained UK MHRA certification; 7 products received EU CE-IVD certification
- 2024: AiChangJian received NMPA Class III registration
- 2025: ＂Certificate Harvest Year＂ - AiXinGan (January), AiSiNing, and AiGuangLe (October) received NMPA Class III registrations, bringing total to 5; revenue reached RMB 15.419 million, up 113% YoY; gross margin improved to 78.1%
- September 28, 2025: Filed first IPO application with Hong Kong Stock Exchange
- April 7, 2026: Filed second IPO application with HKEX after initial filing lapsed; updated prospectus with 2025 financial data
Core Mission: Early, precise, convenient, and accessible cancer detection for all, decoding the tumor ＂black box＂ from hundreds of millions of gene fragments.
Core Technology: AI + Methylation Detection Platform
Proprietary Technology
Emison has built a leADINg methylation-based cancer early detection technology platform combining epigenetics, bioinformatics, materials science, and clinical big data:
- DNA Methylation Localization Technology (DMLT): Core proprietary platform integrating AI-driven multi-omics databases with MLP cancer classifiers
- iTBFinder (Intelligent Tumor Biomarker Finder): AI-powered platform covering over 210,000 data entries from 13,800 patients across 22 cancer types, enabling efficient screening of cancer-specific methylation biomarkers
- SEM-PCR (Sensitivity-Enhanced Methylation PCR): Proprietary technology increasing detection signal intensity by over 10-fold, enabling stAble detection of target genes at concentrations as low as 1 copy/µL
- AS-Cap (Amplification Selective Capture): Proprietary technology enhancing detection sensitivity and specificity
- Dual-Target Detection Innovation: Pioneered dual-target methylation detection (SDC2 + TFPI2) to address left-right colon differences, significantly improving detection sensitivity across the entire colon
- cfDNA Extraction and Conversion: Internally developed specialized cell-free DNA extraction and conversion reagent kits for plasma and urine sample processing
- qPCR-Based Detection: Cost-effective, high-sensitivity quantitative PCR technology for detecting trace circulating tumor DNA (ctDNA) in cell-free DNA (cfDNA)
Core Products and Pipeline
NMPA Class III Approved Products (5 Total)
Emison holds 5 NMPA Class III medical device registrations, ranking first among methylation technology companies in China:
- AiXinGan (艾馨甘, IHepcomf) - Liver Cancer: Global first qPCR-based early liver cancer detection product. Clinical validation: overall sensitivity 92.33%, specificity 93.35%; Stage I liver cancer sensitivity 84.43%, significantly outperforming traditional AFP testing. Approved January 2025. Non-invasive blood test. Included in Beijing Category A and Shanxi Category B medical insurance catalogs
- AiGuangLe (艾光乐, IUrisure) - Urothelial Carcinoma: Non-invasive urine detection using novel methylation biomarkers AL021918.2 and VIM genes. Requires only 1 mL urine sample (vs. 50 mL for competitors). Sensitivity 92.94%, specificity 92.83%; Ta stage sensitivity 85.45%. Approved October 2025. 5th NMPA Class III certificate
- AiChangKang (艾长康, IColocomf) - Colorectal Cancer (Fecal): World's first dual-target fecal DNA methylation detection kit using SDC2 + TFPI2. Sensitivity 95.3%, specificity 93.4%, precancerous lesion detection 63.4%. Single test: 4.5 hours, 1.8 mL sample, 96-sample batch capacity. Approved 2022
- AiChangJian (艾长健, IColohunter) - Colorectal Cancer (Blood): Blood-based methylation detection kit providing alternative non-invasive option. Approved 2024
- AiSiNing (艾思宁, IEsohunter) - Esophageal Cancer: Blood-based methylation detection kit for esophageal cancer. Approved 2025
2025 Revenue Contribution by Product
- AiXinGan: RMB 4.486 million, accounting for 29.1% of total revenue (launched January 2025)
- AiSiNing: RMB 2.317 million, accounting for 15.0% (launched 2025)
- AiChangKang + AiChangJian: Combined RMB 7.416 million, accounting for 48.1%
- AiGuangLe: RMB 0.04 million (pilot revenue; approved October 2025, minimal contribution in 2025)
- Note: AiChangKang revenue declined 12.4% YoY to RMB 4.578 million in 2025, as revenue structure diversified to new products
Pipeline Products (In Development)
- AiGongLe (艾宫乐) - Endometrial Cancer: Endometrial cancer detection using shed cell methylation analysis
- AiWeiYuan (艾卫元) - Gastric Cancer: Early gastric cancer detection candidate
- AiFeiChang (艾斐畅) - Lung Cancer: Early lung cancer detection candidate
- AiLuYuan (艾露元) - Pan-Cancer Multi-Cancer Panel: Multi-cancer joint detection kit covering six high-incidence cancers
International Certifications
- EU CE-IVD: 7 products certified, including AiChangKang, AiChangJian, AiSiNing, AiXinGan, AiGuangLe, and supporting reagent kits
- UK MHRA: AiChangKang and AiChangJian approved for UK and MHRA-recognized markets
- US Patent: 1 US registered patent in addition to 81 Chinese patents
Market Context and Competitive Position
Market Opportunity
- China Tumor Molecular Detection Market: Grew from RMB 4.3 billion in 2019 to RMB 8.7 billion in 2024, projected to reach RMB 38.8 billion by 2033 (CAGR 18.1%)
- Liver Cancer Early Detection Market: RMB 197 million in 2024, projected to reach RMB 3.249 billion by 2033 (CAGR 36.6%)
- Colorectal Cancer Burden: China has 560,000 new colorectal cancer cases annually, but early diagnosis rate is below 20%. Digestive system cancers account for 50% of China's cancer mortality
- Screening Gap: China's colonoscopy USAge rate is only 1/22 of the US, highlighting massive unmet need for non-invasive screening alternatives
Competitive Landscape
- Emison (艾米森): 5 NMPA Class III methylation products, world's first dual-target fecal DNA test, leading in certification count among methylation companies
- Kangliming (康立明生物): ＂ChangAnXin＂ - first NMPA-approved fecal DNA test (2018), single SDC2 target
- Norvo Health (诺辉健康): ＂ChangWeiQing＂ - multi-target FIT-DNA test; delisted from HKEX in October 2025 for failing to meet resumption guidance
- Bolcheng (博尔诚): ＂SiBoDing＂ - blood-based Septin9 test, first blood DNA colorectal test approved in China (2014)
Financial Performance
2025 Annual Results
- Total Revenue: RMB 15.419 million, up 113.03% YoY
- Gross Profit: RMB 12.035 million, up 192.25% from RMB 4.118 million in 2024
- Gross Margin: 78.1% (or 78.05%), up from 56.9% in 2024
- Net Loss Attributable to Owners: RMB 48.979 million, compared to RMB 38.63 million in 2024
- Operating Loss (2024-2025 cumulative): Over RMB 64 million
- Two-Year Cumulative Losses: Approximately RMB 87.6 million versus total revenue of approximately RMB 22.66 million
- Cash and Cash Equivalents: RMB 54.713 million as of December 31, 2025, up from RMB 39.092 million in 2024
- R&D Expenses: RMB 21.297 million in 2025, up 42% YoY, accounting for 138% of revenue
- Administrative Expenses: RMB 20.05 million in 2025, including IPO intermediary fees and RMB 17.61 million share-based payments (non-cash expense)
- Adjusted Operating Loss: Excluding non-cash share-based payments, 2025 operating loss was approximately RMB 31.38 million, narrower than 2024
2024 Annual Results (Baseline)
- Total Revenue: RMB 7.238 million
- Gross Profit: RMB 4.118 million
- Gross Margin: 56.9%
- Net Loss: RMB 38.63 million
- R&D Expenses: RMB 15.0 million
Revenue Drivers
2025 revenue growth driven by:
- Deepening market penetration of approved products (AiChangKang, AiChangJian, AiSiNing)
- Expansion of sales network to 200+ tertiary hospitals across 90 cities
- Launch of AiXinGan (January 2025) and AiSiNing (2025), contributing 44.1% of 2025 revenue combined
- AiChangJian revenue growth exceeding 9x YoY
Company Information and Leadership
Corporate Overview
- Company Full Name: Emison Life Science Technology Co., Ltd. (武汉艾米森生命科技股份有限公司)
- Founded: January 2015
- Headquarters: Wuhan Optics Valley, Hubei Province, China
- Company Type: Private company (IPO candidate)
- Industry: Biotechnology / In Vitro Diagnostics (IVD) / Cancer Early Detection / Molecular Diagnostics
- Research Team: 40 staff as of end-2025, with 65% holding bachelor's degrees or above
- Patent Portfolio: 81 Chinese registered patents (including 59 invention patents) and 1 US registered patent
Leadership Team
Founder, Chairman and CEO: Dr. Zhang Lianglu (张良禄), age 38
- Former pathologist who left clinical practice at age 27 to pursue entrepreneurship in cancer early detection
- Ph.D. in Cell Biology from Wuhan University (obtained June 2022); previously held bachelor's and master's degrees in Bioengineering and Pathology from Wuhan University
- Selected as ＂3551 Optics Valley Talent Plan＂ entrepreneurial talent in 2016
- Led the company through over 10,000 experiments and 1,500+ sample clinical validations
- Vision: Building a comprehensive product matrix covering digestive, gynecological, urological, and pan-cancer detection
Co-founder and R&D President: Dong Lanlan (董兰兰), age 38, Senior Engineer
- Joined Emison in 2016; selected for Optics Valley 3551 Innovative Talent Program
- Led construction of the company's early cancer detection core technology platform and development of multiple cancer detection products
- Applied for over 100 invention patents
HKEX IPO Details (April 2026)
Listing Overview
- Listing Venue: Main Board of Hong Kong Exchanges and Clearing Limited
- Application Date: April 7, 2026 (second filing; initial filing: September 28, 2025, lapsed after 6-month review period)
- Joint Sponsors: CCB International and BOCOM International
- Strategic Significance: If successful, Emison will become Hong Kong's first ＂methylation-based cancer early detection stock＂
- Listing Status: Application under review; prospectus updated with 2025 financial data and AiGuangLe approval status
Challenges and Risks
- Profitability: Company remains in losses with 2025 net loss of RMB 48.98 million; prospectus warns that losses may continue in 2026
- Revenue Scale: Annual revenue still in the tens of millions of RMB, relatively small compared to industry peers (e.g., Ranshi Medical revenue RMB 516 million in 2024)
- Regulatory Definition: Products registered for ＂detection/辅助诊断＂ rather than ＂screening＂ for healthy asymptomatic populations; true cancer screening approval requires proof of mortality reduction in large-scale clinical trials
- Related Party Transactions: Historical revenue included significant proportions from related party transactions (Zhang Lianglu's wholly-owned Wuhan Ainuo Medical Laboratory was a major customer)
- Customer Concentration: Top 5 customers accounted for substantial revenue share; risk of customer concentration
- Commercialization Risk: Prospectus states ＂We may not ultimately succeed in developing and commercializing new indications for AiXinGan and AiGuangLe, or any or all of our pipeline products＂
2026 Outlook and Strategic Focus
Future Development Priorities
- HKEX Listing: Complete Hong Kong IPO to secure capital for commercialization scale-up and brand recognition
- AiGuangLe Commercialization: Accelerate market launch of AiGuangLe (approved October 2025), targeting urothelial carcinoma recurrence monitoring indication
- AiXinGan Scale-Up: Leverage medical insurance coverage (Beijing Category A, Shanxi Category B) to drive hospital adoption and revenue growth
- Hospital Network Expansion: Expand beyond 200+ tertiary hospitals in 90 cities to cover more secondary hospitals and体检 centers
- Pipeline Advancement: Advance 4 candidate products (AiGongLe, AiWeiYuan, AiFeiChang, AiLuYuan) toward clinical trials and regulatory approval
- International Expansion: Leverage CE-IVD and MHRA certifications to enter European and Commonwealth markets
- Cost Optimization: Improve gross margin further through production scale effects; target break-even as revenue scales beyond RMB 50-100 million
- R&D Efficiency: Manage R&D intensity while advancing pipeline; 2025 R&D-to-revenue ratio was 138%, requiring careful capital allocation post-IPO
Contact Information
China Headquarters
- Address: Wuhan Optics Valley, Hubei Province, China
- Website: www.ammulifetech.com
Keywords: Emison, 艾米森, 武汉艾米森, cancer early detection, methylation detection, colorectal cancer, liver cancer, esophageal cancer, urothelial carcinoma, AiXinGan, 艾馨甘, AiChangKang, 艾长康, AiGuangLe, 艾光乐, AiChangJian, 艾长健, AiSiNing, 艾思宁, NMPA Class III, Hong Kong IPO, HKEX, CCB International, BOCOM International, Zhang Lianglu, 张良禄, Dong Lanlan, 董兰兰, Wuhan, China, fecal DNA, blood DNA, urine DNA, qPCR, ctDNA, cfDNA, early diagnosis, tumor screening, SDC2, TFPI2, AL021918.2, VIM, CE-IVD, MHRA, iTBFinder, SEM-PCR, AS-Cap, DMLT, Optics Valley, medical insurance, Beijing, Shanxi
